Advertisement

 

 

Sex Differences in Select Non-communicable HIV-Associated Comorbidities: Exploring the Role of Systemic Immune Activation/Inflammation.

Sex Differences in Select Non-communicable HIV-Associated Comorbidities: Exploring the Role of Systemic Immune Activation/Inflammation.
Author Information (click to view)

Raghavan A, Rimmelin DE, Fitch KV, Zanni MV,


Raghavan A, Rimmelin DE, Fitch KV, Zanni MV, (click to view)

Raghavan A, Rimmelin DE, Fitch KV, Zanni MV,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Current HIV/AIDS reports 2017 10 27() doi 10.1007/s11904-017-0366-8

Abstract
PURPOSE OF THE REVIEW
The goals of this review are to (1) explore HIV-associated cardiovascular disease (CVD), neurocognitive impairment, and non-AIDS-defining cancers (NADC) as heterogeneous model disease states fuelled in part by systemic immune activation/inflammation; (2) consider sex differences in the epidemiology of these diseases in both high-resource and lower-resource settings; and (3) examine biological and environmental factors which may contribute to heightened systemic immune activation/inflammation specifically among women living with HIV (WLHIV).

RECENT FINDINGS
The observation that WLHIV have higher levels of systemic immune activation/inflammation than men living with HIV (MLHIV) may be relevant to sex differences in select non-communicable HIV-associated comorbidities. Heightened systemic immune activation among WLHIV may be influenced by sex-specific responses to the virus and to immunomodulatory agents, as well as by behavioral choices/comorbid conditions and perturbations in the hypothalamic-pituitary-gonadal axis. Additional research is needed to elucidate region-specific drivers of heightened systemic immune activation/inflammation among WLHIV and to determine whether WLHIV who present with one immune-mediated HIV-associated comorbidity (e.g., cognitive impairment) may be at increased risk for another (e.g., CVD, NADC). This kind of research would facilitate improved risk prediction for non-communicable HIV-associated comorbidities among WLHIV and the development of targeted immunomodulatory prevention strategies.

Submit a Comment

Your email address will not be published. Required fields are marked *

five × 5 =

[ HIDE/SHOW ]